StreetInsider.com News Articles

Form 8-K Ocugen, Inc. For: Jul 13

Mon, 13 Jul 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260713/26760286.html

Form 8-K Ocugen, Inc. For: Jul 13

Mon, 13 Jul 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260713/26760286.html

Ocugen signs MENA licensing deal for OCU400 gene therapy

Mon, 13 Jul 2026 07:03:18 -0400

Ocugen, Inc. (NASDAQ: OCGN) has signed a binding term sheet with Roots Pharmaceutical and its strategic partner Al-Dhow International Holding to negotiate an exclusive license agreement for OCU400, its modifier gene therapy for Retinitis Pigmentosa, in the Middle East and North Africa region.

Under the terms outlined in the agreement, Ocugen would receive upfront license fees and near-term development milestone payments totaling up to $4 million. The company would also be eligible for cumulative sales milestone payments of up to $255 million, along with a 22% royalty on net sales generated by its partner. Ocugen would manufacture and supply OCU400 under

Ocugen signs MENA licensing deal for OCU400 gene therapy

Mon, 13 Jul 2026 07:03:18 -0400

Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa

Mon, 13 Jul 2026 07:02:00 -0400

Cumulative sales milestones up to $255 million and modest upfront/near-term development milestones
Royalties equaling 22% of net sales
Ocugen to manufacture and supply OCU400

MALVERN, Pa., July 13, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the signing of a binding term sheet to negotiate and enter into a license agreement with Roots Pharmaceutical, and its strategic partner Al-Dhow International Holding, for the exclusive rights to OCU400, Ocugen's novel modifier gene therapy for Retinitis Pigmentosa (RP), in the Middle East and

Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa

Mon, 13 Jul 2026 07:02:00 -0400

Cumulative sales milestones up to $255 million and modest upfront/near-term development milestones
Royalties equaling 22% of net sales
Ocugen to manufacture and supply OCU400

Ocugen to Participate in Upcoming July Industry Conferences

Wed, 01 Jul 2026 07:00:00 -0400

MALVERN, Pa., July 01, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming investor and industry conferences in July 2026.

Piper Sandler Virtual Ophthalmology Day – Fireside Chat

Date: Friday, July 10, 2026
Time: 10:00–10:25 a.m. EDT
Speaker: Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder, Ocugen
Moderator: Biren Amin, Managing Director, Healthcare Equity Research, Piper Sandler & Co.

OIS (Ophthalmology Innovation Source) Retina Innovation Summit

Ocugen to Participate in Upcoming July Industry Conferences

Wed, 01 Jul 2026 07:00:00 -0400

Piper Sandler Virtual Ophthalmology Day – Fireside Chat

OIS (Ophthalmology Innovation Source) Retina Innovation Summit

Form 4 Ocugen, Inc. For: Jun 15 Filed by: Johnson-Greene Treerita Essalima

Wed, 17 Jun 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260617/26660033.html

Form 4 Ocugen, Inc. For: Jun 15 Filed by: Johnson-Greene Treerita Essalima

Wed, 17 Jun 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260617/26660033.html

Form 4 Ocugen, Inc. For: Jun 11 Filed by: Kompella Uday

Mon, 15 Jun 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260615/26647956.html

Form 4 Ocugen, Inc. For: Jun 11 Filed by: Kompella Uday

Mon, 15 Jun 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260615/26647956.html

Form 4 Ocugen, Inc. For: Jun 11 Filed by: Chandrasekhar Satishchandran

Mon, 15 Jun 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260615/26647941.html

Form 4 Ocugen, Inc. For: Jun 11 Filed by: Chandrasekhar Satishchandran

Mon, 15 Jun 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260615/26647941.html

Form 4 Ocugen, Inc. For: Jun 11 Filed by: Castillo Kirsten

Mon, 15 Jun 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260615/26647921.html

Form 4 Ocugen, Inc. For: Jun 11 Filed by: Castillo Kirsten

Mon, 15 Jun 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260615/26647921.html

Form 4 Ocugen, Inc. For: Jun 11 Filed by: Coleman Blaise

Mon, 15 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260615/26647865.html

Form 4 Ocugen, Inc. For: Jun 11 Filed by: Coleman Blaise

Mon, 15 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260615/26647865.html

Form 4 Ocugen, Inc. For: Jun 11 Filed by: Zhang Junge

Mon, 15 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260615/26647898.html

Form 4 Ocugen, Inc. For: Jun 11 Filed by: Zhang Junge

Mon, 15 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260615/26647898.html

Form 8-K Ocugen, Inc. For: Jun 11

Thu, 11 Jun 2026 17:19:00 -0400

si-local-file:///var/storage/secattach/20260611/26636805.html

Form 8-K Ocugen, Inc. For: Jun 11

Thu, 11 Jun 2026 17:19:00 -0400

si-local-file:///var/storage/secattach/20260611/26636805.html

Form 8-K Ocugen, Inc. For: May 29

Wed, 03 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260603/26599465.html

Form 8-K Ocugen, Inc. For: May 29

Wed, 03 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260603/26599465.html

Ocugen to Participate in Upcoming June Investor and Industry Conferences

Tue, 02 Jun 2026 07:03:00 -0400

MALVERN, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming investor and industry conferences in June 2026.

Noble Capital Markets June 2026 Emerging Growth Virtual Equity Conference

Date: Thursday, June 4, 2026
Time: 2:30pm EDT

Clinical Trials at the Summit 2026

Location: Fontainebleau Las Vegas
Date: Saturday, June 13, 2026
Time: 10:19 – 10:39